Skip to main content
Sign In

Elaine Lam, MD

Assistant Professor, Division of Medical Oncology

Elaine Lam, MD            



University of Colorado, June 2003

Dr. Lam joined the division of Medical Oncology as an
Assistant Professor of Medicine at UCD on October 1, 2010.
She previously worked as a clinical pharmacist prior to
attending medical school and completing her residency at the University of Colorado, followed by fellowship training at The
Ohio State University. Outside of medicine, she enjoys
spending time with her husband and their two children.

Dr. Lam's clinical focus is in genitourinary malignancies and
her research interest is in the development of novel targeted
agents.  Dr. Lam is involved with clinical research and patient
care in the Urologic Oncology Program, as well as, the
Developmental Therapeutics Program.

Lam ET, O’Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt G, and Gore L.  A Phase I Study of Gefitinib, Capecitabine, and Celecoxib In Patients With Advanced Solid Tumors. Mol Cancer Ther 2008;7(12):3685-94.  PMID: 19074845.

Lam ET, Au JS, Otterson GA, Guillaume-Wientjes M, Chen L, Shen T, Wei Y, Young D, Murgo AJ, Jenson RR, Grever M, and Villalona-Calero MA.  A Phase I Trial of Non-cytotoxic Suramin as Modulator of Docetaxel and Gemcitabine Therapy in Previously Treated Non-Small Cell Lung Cancer.  Cancer Chemother Pharmacol, Epub ahead of print 2010 Jan 28, doi:10.1007/s00280-010-1252-x.  PMID: 20107799

Lam ET, Ringel MD, Kloos RT, Prior T, Knopp MV, Vasko V, Liang J, Sammet S, Hall NC, Wakely PE, Motoyasu S, Snyder P, Wei L, Arbogast D, Collamore M, Wright JJ, Moley J, Villalona-Calero MA, and Shah MH.  A Phase II Clinical Trial of the Multi-Kinase Inhibitor, Sorafenib, in Metastatic Medullary Thyroid Cancer.  J Clin Oncol, 2010;28(14):2323-30. Epub ahead of print 2010 Apr 5, doi:10.1200/JCO.2009.25.0068.  PMID: 20368568.

Lam ET, Goel S, Schaaf L, McCracken B, Desai K, Cropp GF, Zhou Y, Johnson RG, Hannah AI, Mani S, and Villalona-Calero MA.  Phase I Dose Escalation Trial of the Novel Epothilone KOS-1584 in Patients with Advanced Solid Tumors (Submitted)

PubMed Articles​​